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A B S T R A C T
Inclusion body myositis (IBM) is the commonest idiopathic inﬂammatory myopathy of older persons.
Pathophysiological mechanism of IBM remains unknown; however, an association of IBM with chronic hepatitis
C virus (HCV) infection and serum autoantibodies against skeletal muscle protein 5′-nucleotidase 1A (NT5C1A)
has recently been reported. No eﬀective treatment for IBM has yet been developed. We here present a 70-year-
old man who was anti-NT5C1A antibody-positive in association with IBM and chronic hepatitis C. The initial
treatment of ombitasvir/paritaprevir/ritonavir for his chronic hepatitis C was successful; however, his symptoms
of IBM did not improve. On the contrary, his quadriplegic paralysis became more severe and he developed
dysphagia. Next, steroid pulse therapy was initiated for IBM and, although his hyper-creatine phosphokinase-
emia improved, his symptoms did not; indeed, they worsened. Subsequent intravenous immunoglobulin therapy
(IVIg) resulted in obvious improvement in his dysphagia. Thereafter IVIg therapy was repeated at approximately
2-monthly intervals. His dysphagia remained improved for more than 1 year; however, his quadriplegia con-
tinued to progress slowly. Although IBM can reportedly be associated with hepatitis C, we inferred that there was
no direct relationship between these conditions in our patient because his IBM did not improve after treatment of
his hepatitis C. Although his IBM-associated quadriplegia did not improve, IVIg therapy did result in im-
provement in his dysphagia.
1. Introduction
Inclusion body myositis (IBM), the most common idiopathic in-
ﬂammatory myopathy of older persons, is characterized clinically by
asymmetric ﬁnger ﬂexor and knee extensor weakness and histologically
by lymphocytic endomysial inﬂammation and autophagic rimmed va-
cuoles [1]. The pathophysiological mechanism of sporadic IBM remains
unknown; however, an association between IBM and chronic hepatitis C
virus (HCV) infection was recently reported [2,3]. Furthermore, serum
autoantibodies against skeletal muscle protein 5′-nucleotidase 1A
(NT5C1A) is reportedly a relatively speciﬁc diagnostic marker for IBM
[4,5].
2. Case report
A 70-year-old man had diﬃculty climbing stairs because of weak-
ness of both lower limbs and did not improve despite undergoing re-
habilitation. These symptoms slowly worsened over a 1-year period,
during which he had diﬃculty walking and the grip strength of both
hands weakened, prompting admission to our hospital. He presented
with predominantly left-sided proximal leg, particularly quadriceps
muscle, weakness, ﬁnger ﬂexor muscle weakness, and atrophy. Serum
creatine phosphokinase (CPK) concentration was slightly increased
(650 IU/L). The histopathological ﬁndings on a biopsy of the rectus
femoris muscle performed two months after ﬁrst visit to our hospital
were consistent with IBM in that he had marked endomysial ﬁbrosis
with lymphocyte inﬁltration partially surrounding non-necrotic muscle
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ﬁbers and muscle ﬁbers with rimmed vacuoles. Furthermore, anti-
NT5C1A antibodies were detected in the patient's serum by cell-based
assay [5], and he had mild liver dysfunction caused by chronic hepatitis
C (virus genotype 1b, serum HCV RNA concentration 5.9 logIU/mL). He
was initially treated with ombitasvir/paritaprevir/ritonavir for hepa-
titis C for 3months, which resulted in improvement in his liver function
and negative conversion of HCV-RNA. However, his hyper-CPKemia
persisted, accompanied by progression of limb muscle weakness and he
began to develop dysphagia. In order to conﬁrm the response to steroid
hormones, steroid pulse therapy (methylprednisolone 500mg/day for 3
consecutive days) was administered about 2months after HCV treat-
ment because an autoimmune mechanism was suspected due to anti-
NT5C1A antibody positivity, in addition to the histopathological ﬁnd-
ings of myositis with no signiﬁcant clinical improvement other than an
improvement in his hyper-CPKemia. Subsequent intravenous im-
munoglobulin (IVIg) (400mg/kg/day for 5 consecutive days) was ad-
ministered 1.5 months after steroid administration, which improved his
dysphagia (Video 1, 2). Thereafter, IVIg treatment was continued at 2-
month intervals. His dysphagia remained improved over a year; how-
ever, his quadriplegic paralysis continued to become more severe, re-
sulting in diﬃculty standing and walking.
3. Discussion
There are currently no eﬀective treatments for IBM. Adrenocortical
hormone preparations are often administered as for polymyositis/der-
matomyositis; however, many patients are refractory to this treatment,
evidencing slowly progressive muscle weakness even though serum
CPK concentrations decline [1]. A relationship between IBM and HCV
infection has been reported [2,3], necessitating monitoring for HCV
reactivation associated with treatment with steroid hormones or im-
munosuppressants; however, there are no reports of IBM improving
with treatment of HCV. Consistent with this, our patient's symptoms did
not improve after successful treatment of HCV. Even after resolution of
hepatitis, hyper-CPKemia continued and his limb strength was also
reduced. Thus, although HCV may be associated with the onset of IBM,
it is not considered to be directly associated with the progression of the
pathological condition.
It has been proposed that seropositivity for NT5C1A antibody is
associated with severity of dysphagia [6]. A double-blind comparative
study has not yielded a signiﬁcant diﬀerence between IVIg therapy and
placebo to date [1]. However, IVIg therapy is reportedly eﬀective for
dysphagia and thus may be worth trying, especially when the dysphagia
is relatively mild [7]. Our patient's symptoms did not improve with
administration of steroid hormones; his quadriplegic paralysis pro-
gressed, as did his dysphagia. Subsequent IVIg therapy was associated
with obvious improvement in his dysphagia. Thereafter IVIg therapy at
2-month intervals stabilized his swallowing for more than 1 year;
however, his quadriplegia and muscle atrophy progressed. Although no
eﬀective treatment has yet been developed for quadriplegia associated
with IBM, it is worth trying IVIg therapy for IBM-associated dysphagia.
Supplementary data to this article can be found online at https://
doi.org/10.1016/j.ensci.2019.100204.
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